All Stories

  1. Exploring algorithms to select candidates for non-selective beta-blockers in cirrhosis: A post hoc analysis of the PREDESCI trial

    Article • Journal of Hepatology, March 2025, Elsevier

    Dr Joan Genesca

  2. Progressive systemic inflammation precedes decompensation in compensated cirrhosis

    Article • JHEP Reports, February 2025, Elsevier

    Dr Joan Genesca

  3. Porto-sinusoidal vascular liver disorder with portal hypertension: Natural history and long-term outcome

    Article • Journal of Hepatology, January 2025, Elsevier

    Dr Joan Genesca

  4. Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD

    Article • Journal of Hepatology, November 2024, Elsevier

    Dr Joan Genesca

  5. Zinc supplementation to improve prognosis in patients with compensated advanced chronic liver disease: a multicenter, randomized, double-blind, placebo-controlled clinical trial

    Article • Hepatology Communications, October 2024, Wolters Kluwer Health

    Dr Joan Genesca

  6. Cost-Effectiveness of the Baveno VI Criteria Compared With Endoscopy for High-Risk Varices in Patients With Child-Pugh A Cirrhosis

    Article • Clinical Gastroenterology and Hepatology, October 2024, Elsevier

    Dr Joan Genesca

  7. Noninvasive Assessment of Portal Hypertension

    Article • Clinics in Liver Disease, August 2024, Elsevier

    Dr Joan Genesca

  8. Relationship between updated MELD and prognosis in alcohol-associated hepatitis: Opportunities for more efficient trial design

    Article • Hepatology Communications, July 2024, Wolters Kluwer Health

    Dr Joan Genesca

  9. Alcohol consumption and liver phenotype of individuals with alpha‐1 antitrypsin deficiency

    Article • Liver International, July 2024, Wiley

    Dr Joan Genesca

  10. A roadmap for clinical trials in MASH-related compensated cirrhosis

    Article • Nature Reviews Gastroenterology & Hepatology, July 2024, Springer Science + Business Media

    Dr Joan Genesca

  11. Needs assessment for creation of a platform trial network in metabolic-dysfunction associated steatohepatitis

    Article • Communications Medicine, July 2024, Springer Science + Business Media

    Dr Joan Genesca

  12. Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure

    Article • Hepatology, July 2024, Wolters Kluwer Health

    Dr Joan Genesca

  13. Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure

    Article • Journal of Hepatology, July 2024, Elsevier

    Dr Joan Genesca

  14. Current state-of-the-art and gaps in platform trials: 10 things you should know, insights from EU-PEARL

    Article • EClinicalMedicine, January 2024, Elsevier

    Martin Posch, Dr Joan Genesca

  15. Quantifying the benefit of nonselective beta-blockers in the prevention of hepatic decompensation: A Bayesian reanalysis of the PREDESCI trial

    Article • Hepatology, March 2023, Wolters Kluwer Health

    Dr Joan Genesca

  16. Metabolomics as a tool to predict the risk of decompensation or liver-related death in patients with compensated cirrhosis

    Article • Hepatology, February 2023, Wolters Kluwer Health

    Dr Joan Genesca

  17. Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and cons

    Article • Journal of Hepatology, February 2023, Elsevier

    Dr Joan Genesca

  18. Liver steatosis induces portal hypertension regardless of fibrosis in patients with NAFLD: A proof of concept case report

    Article • JHEP Reports, January 2023, Elsevier

    Dr Joan Genesca

  19. Noninvasive predictors of clinically significant portal hypertension in NASH cirrhosis: Validation of ANTICIPATE models and development of a lab‐based model

    Article • Hepatology Communications, October 2022, Wolters Kluwer Health

    Dr Joan Genesca

  20. A Nine-Strain Bacterial Consortium Improves Portal Hypertension and Insulin Signaling and Delays NAFLD Progression In Vivo

    Article • Biomedicines, May 2022, MDPI AG

    Dr Joan Genesca

  21. Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis

    Article • JHEP Reports, December 2021, Elsevier

    Dr Joan Genesca

  22. Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?

    Article • Journal of Hepatology, September 2021, Elsevier

    Dr Joan Genesca

  23. Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis

    Article • Journal of Hepatology, September 2021, Elsevier

    Dr Joan Genesca

  24. Reply to: “Evaluating the role of transient elastography post chronic hepatitis C treatment to predict hepatocellular carcinoma”

    Article • Journal of Hepatology, November 2020, Elsevier

    Dr Joan Genesca

  25. Steatosis as main determinant of portal hypertension through a restriction of hepatic sinusoidal area in a dietary rat nash model

    Article • Liver International, October 2020, Wiley

    Dr Joan Genesca

  26. <p>Trends in Diagnosis of Alpha-1 Antitrypsin Deficiency Between 2015 and 2019 in a Reference Laboratory</p>

    Article • International Journal of Chronic Obstructive Pulmonary Disease, October 2020, Taylor & Francis

    Dr Joan Genesca

  27. Reply to: “Hepatocellular carcinoma surveillance after hepatitis C virus eradication: Is liver stiffness measurement more useful than laboratory fibrosis markers?” and “External validation of noninvasive predictors of hepatocellular carcinoma in patien...

    Article • Journal of Hepatology, August 2020, Elsevier

    Dr Joan Genesca

  28. Restoration of liver sinusoidal cell phenotypes by statins improves portal hypertension and histology in rats with NASH

    Article • Scientific Reports, December 2019, Springer Science + Business Media

    Dr Joan Genesca

  29. Beyond Baveno VI: How far are we?

    Article • Digestive and Liver Disease, August 2019, Elsevier

    Dr Joan Genesca

  30. Preemptive‐TIPS Improves Outcome in High‐Risk Variceal Bleeding: An Observational Study

    Article • Hepatology, December 2018, Wiley

    Dr Joan Genesca, Clinical Chair Professor Henning Gronbaek

  31. Should prophylactic embolization of spontaneous portosystemic shunts be routinely performed during transjugular intrahepatic portosystemic shunt placement?

    Article • Digestive and Liver Disease, June 2018, Elsevier

    Dr Joan Genesca

  32. Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis

    Article • Hepatology, February 2018, Wiley

    Dr Joan Genesca

  33. Duration of the acute hepatic encephalopathy episode determines survival in cirrhotic patients

    Article • Therapeutic Advances in Gastroenterology, November 2017, SAGE Publications

    Dr Joan Genesca

  34. Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease

    Article • Hepatology, October 2017, Wiley

    Dr Joan Genesca

  35. Correction

    Article • Hepatology, June 2017, Wiley

    Dr Joan Genesca

  36. Enfermedades vasculares del hígado. Guías Clínicas de la Sociedad Catalana de Digestología y de la Asociación Española para el Estudio del Hígado

    Article • Gastroenterología y Hepatología, June 2017, Elsevier

    Dr Joan Genesca

  37. Multicenter External Validation of Risk Stratification Criteria for Patients With Variceal Bleeding

    Article • Clinical Gastroenterology and Hepatology, May 2017, Elsevier

    Dr Joan Genesca

  38. Risk Stratification in Acute Variceal Bleeding

    Article • Journal of Clinical Gastroenterology, April 2017, Wolters Kluwer Health

    Dr Joan Genesca

  39. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study

    Article • Hepatology, March 2017, Wiley

    Dr Joan Genesca

  40. High HCV subtype heterogeneity in a chronically infected general population revealed by high-resolution hepatitis C virus subtyping

    Article • Clinical Microbiology and Infection, February 2017, Elsevier

    Dr Joan Genesca

  41. Validating the Baveno VI recommendations for screening varices

    Article • Journal of Hepatology, February 2017, Elsevier

    Dr Joan Genesca

  42. A Nitric Oxide-Donating Statin Decreases Portal Pressure with a Better Toxicity Profile than Conventional Statins in Cirrhotic Rats

    Article • Scientific Reports, January 2017, Nature

    Dr Joan Genesca

  43. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis

    Article • Liver International, November 2016, Wiley

    Dr Joan Genesca, Clinical Chair Professor Henning Gronbaek

  44. Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The “Anticipate” study

    Article • Hepatology, October 2016, Wiley

    Dr Joan Genesca

  45. Impact of ornithine phenylacetate (OCR-002) in lowering plasma ammonia after upper gastrointestinal bleeding in cirrhotic patients

    Article • Therapeutic Advances in Gastroenterology, July 2016, SAGE Publications

    Dr Joan Genesca, Dr Beatriz Mínguez

  46. Cerebellar neurodegeneration in a new rat model of episodic hepatic encephalopathy

    Article • Journal of Cerebral Blood Flow & Metabolism, July 2016, SAGE Publications

    Laia Chavarria, Dr Joan Genesca

  47. Basal values and changes of liver stiffness predict the risk of disease progression in compensated advanced chronic liver disease

    Article • Digestive and Liver Disease, June 2016, Elsevier

    Dr Joan Genesca

  48. Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis

    Article • Gastroenterology, May 2016, Elsevier

    Dr Joan Genesca, Dr Juan G Abraldes

  49. Ruling in and ruling out with elastography in compensated advanced chronic liver disease

    Article • Gut, March 2016, BMJ

    Dr Joan Genesca

  50. α1 and α2-adrenergic agonists on cirrhotic patients with refractory ascites

    Article • Liver International, January 2016, Wiley

    Dr Joan Genesca

  51. Consensus Statements: Session 1—Screening and Surveillance

    Article • January 2016, Springer Science + Business Media

    Dr Joan Genesca

  52. Identifying Compensated Advanced Chronic Liver Disease: When (Not) to Start Screening for Varices and Clinically Significant Portal Hypertension

    Article • January 2016, Springer Science + Business Media

    Dr Joan Genesca

  53. Erratum to: Chapter 9 in Consensus Statements: Session 1—Screening and Surveillance

    Article • January 2016, Springer Science + Business Media

    Dr Joan Genesca

  54. Evaluación y tratamiento del paciente cirrótico crítico

    Article • Gastroenterología y Hepatología, January 2016, Elsevier

    Dr Joan Genesca

  55. Alcohol consumption and risk of infection after a variceal bleeding in low-risk patients

    Article • Liver International, December 2015, Wiley

    Dr Joan Genesca

  56. Development of hyperdynamic circulation and response to β-blockers in compensated cirrhosis with portal hypertension

    Article • Hepatology, November 2015, Wiley

    Dr Joan Genesca

  57. Reply to “Points to be considered when using transient elastography for diagnosis of portal hypertension according to the Baveno’s VI consensus”

    Article • Journal of Hepatology, October 2015, Elsevier

    Dr Joan Genesca

  58. Expanding consensus in portal hypertension

    Article • Journal of Hepatology, September 2015, Elsevier

    Dr Joan Genesca

  59. Impact of anticoagulation on upper-gastrointestinal bleeding in cirrhosis. A retrospective multicenter study

    Article • Hepatology, April 2015, Wiley

    Professor Juan Carlos Garcia-Pagán, Dr Joan Genesca

  60. O017A : Non-invasive tools and risk of varices and clinically significant portal hypertension in compensated cirrhosis: the “anticipate” study

    Article • Journal of Hepatology, April 2015, Elsevier

    Dr Joan Genesca

  61. P0102 : Degeneration signs of Purkinje neurons in a new animal model of episodic hepatic encephalopathy

    Article • Journal of Hepatology, April 2015, Elsevier

    Dr Joan Genesca

  62. Rebleeding prophylaxis improved outcomes in patients with hepatocellular carcinoma: Is it feasible in all patients?

    Article • Hepatology, November 2014, Wolters Kluwer Health

    Dr Joan Genesca

  63. O167 ADDITION OF SIMVASTATIN TO STANDARD TREATMENT IMPROVES SURVIVAL AFTER VARICEAL BLEEDING IN PATIENTS WITH CIRRHOSIS. A DOUBLE-BLIND RANDOMIZED TRIAL (NCT01095185)

    Article • Journal of Hepatology, April 2014, Elsevier

    Dr Joan Genesca

  64. Detection of early portal hypertension with routine data and liver stiffness in patients with asymptomatic liver disease: A prospective study

    Article • Journal of Hepatology, March 2014, Elsevier

    Dr Joan Genesca

  65. The renal effects of droxidopa are maintained in propranolol treated cirrhotic rats

    Article • Liver International, February 2014, Wiley

    Dr Joan Genesca

  66. A MELD-Based Model to Determine Risk of Mortality Among Patients With Acute Variceal Bleeding

    Article • Gastroenterology, February 2014, Elsevier

    Dr Juan G Abraldes, Dr Joan Genesca

  67. Inhibition of Neuronal Apoptosis and Axonal Regression Ameliorates Sympathetic Atrophy and Hemodynamic Alterations in Portal Hypertensive Rats

    Article • PLOS One, January 2014, PLOS

    Dr Joan Genesca

  68. Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study

    Article • Hepatology, October 2013, Wiley

    Dr Juan G Abraldes, Dr Joan Genesca

  69. 602 HEMODYNAMIC EFFECTS OF A COMBINED ACUTE TREATMENT WITH A NON-SELECTIVE BETA BLOCKER PLUS DROXIDOPA IN CIRRHOTIC RATS

    Article • Journal of Hepatology, April 2013, Elsevier

    Dr Joan Genesca

  70. Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats

    Article • Hepatology, October 2012, Wiley

    Dr Joan Genesca

  71. Long-term follow-up of hemodynamic responders to pharmacological therapy after variceal bleeding

    Article • Hepatology, July 2012, Wiley

    Dr Joan Genesca

  72. Hipertensión portal: recomendaciones para su evaluación y tratamiento

    Article • Gastroenterología y Hepatología, June 2012, Elsevier

    Dr Juan G Abraldes, Dr Joan Genesca

  73. 574 ALTERED NEUROMODULATOR EXPRESION WITHIN THE SUPERIOR MESENTERIC GANGLIA MAY CAUSE SYMPATHETIC ATROPHY IN PORTAL HYPERTENSIVE RATS

    Article • Journal of Hepatology, April 2012, Elsevier

    Dr Joan Genesca

  74. 609 A SIMPLE DIAGNOSTIC STRATEGY BASED ON ROUTINE CLINICAL DATA AND TRANSIENT ELASTOGRAPHY ACCURATELY DETECTS EARLY PORTAL HYPERTENSION IN PATIENTS WITH ASYMPTOMATIC LIVER DISEASE

    Article • Journal of Hepatology, April 2012, Elsevier

    Dr Joan Genesca

  75. Blockage of the afferent sensitive pathway prevents sympathetic atrophy and hemodynamic alterations in rat portal hypertension

    Article • Liver International, January 2012, Wiley

    Dr Joan Genesca

  76. Adding banding ligation is effective as rescue therapy to prevent variceal rebleeding in haemodynamic non-responders to pharmacological therapy

    Article • Digestive and Liver Disease, January 2012, Elsevier

    Dr Joan Genesca

  77. Effectiveness of Combined Pharmacologic and Ligation Therapy in High-Risk Patients With Acute Esophageal Variceal Bleeding

    Article • The American Journal of Gastroenterology, May 2011, Wolters Kluwer Health

    Dr Joan Genesca

  78. 598 HEMODYNAMIC AND RENAL EFFECTS OF AN ORAL PRODRUG OF NOREPINEPHRINE IN PORTAL HYPERTENSIVE RATS

    Article • Journal of Hepatology, March 2011, Elsevier

    Dr Joan Genesca

  79. 597 EFFECT OF NEONATAL CAPSAICIN TREATMENT ON SYMPATHETIC ATROPHY AND HEMODYNAMIC ALTERATIONS OF PORTAL HYPERTENSIVE RATS

    Article • Journal of Hepatology, March 2011, Elsevier

    Dr Joan Genesca

  80. 934 LONG-TERM FOLLOW-UP OF HEMODYNAMIC RESPONDERS TO PHARMACOLOGICAL THERAPY AFTER VARICEAL BLEEDING: A COHORT-STUDY

    Article • Journal of Hepatology, March 2011, Elsevier

    Dr Joan Genesca

  81. Diagnostic and Prognostic Markers in Liver Cirrhosis

    Article • Disease Markers, January 2011, Hindawi Publishing Corporation

    Dr Joan Genesca

  82. Prognostic Evaluation of Patients with Acute Variceal Bleeding

    Article • Disease Markers, January 2011, Hindawi Publishing Corporation

    Dr Joan Genesca

  83. High doses of β-blockers and alcohol abstinence improve long-term rebleeding and mortality in cirrhotic patients after an acute variceal bleeding

    Article • Liver International, May 2010, Wiley

    Dr Joan Genesca

  84. Atrophy of mesenteric sympathetic innervation may contribute to splanchnic vasodilation in rat portal hypertension

    Article • Liver International, April 2010, Wiley

    Dr Joan Genesca

  85. 509 THE ABLATION OF THE AFFERENT SENSITIVE PATHWAY PREVENTS SYMPATHETIC ATROPHY AND HEMODYNAMIC ALTERATIONS DURING PORTAL HYPERTENSION

    Article • Journal of Hepatology, April 2010, Elsevier

    Dr Joan Genesca

  86. 840 ENDOSCOPIC VARICEAL LIGATION IS HIGHLY EFFECTIVE IN THE PREVENTION OF VARICEAL REBLEEDING IN HEMODYNAMIC NON-RESPONDERS TO PHARMACOLOGICAL THERAPY

    Article • Journal of Hepatology, April 2010, Elsevier

    Dr Joan Genesca

  87. Physiopathology of splanchnic vasodilation in portal hypertension

    Article • World Journal of Hepatology, January 2010, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Dr Joan Genesca

  88. Acute esophageal variceal bleeding: Current strategies and new perspectives

    Article • World Journal of Hepatology, January 2010, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Dr Joan Genesca

  89. Predicting Early Mortality After Acute Variceal Hemorrhage Based on Classification and Regression Tree Analysis

    Article • Clinical Gastroenterology and Hepatology, December 2009, Elsevier

    Dr Joan Genesca

  90. 208 LONG-TERM OUTCOME OF CIRRHOTIC PATIENTS AFTER AN EPISODE OF VARICEAL BLEEDING: ANALYSIS OF PROGNOSTIC FACTORS

    Article • Journal of Hepatology, April 2009, Elsevier

    Dr Joan Genesca

  91. 176 PROGNOSTIC ASSESSMENT OF EARLY MORTALITY AFTER ACUTE VARICEAL HAEMORRHAGE BASED ON CLASSIFICATION AND REGRESSION TREE ANALYSIS

    Article • Journal of Hepatology, April 2009, Elsevier

    Dr Joan Genesca

  92. Disappearance of serum hepatitis B virus DNA by polymerase chain reaction after adenine arabinoside 5‘-monophosphate therapy in chronic hepatitis B

    Article • Liver International, December 2008, Wiley

    Dr Joan Genesca

  93. Role of host and bacterial virulence factors in Escherichia coli spontaneous bacterial peritonitis

    Article • European Journal of Gastroenterology & Hepatology, September 2008, Wolters Kluwer Health

    Dr Joan Genesca

  94. Valor del gradiente de presión hepática en el pronóstico de la cirrosis compensada

    Article • Gastroenterología y Hepatología Continuada, August 2008, Elsevier

    Dr Joan Genesca

  95. Down-regulation of genes related to the adrenergic system may contribute to splanchnic vasodilation in rat portal hypertension

    Article • Journal of Hepatology, July 2008, Elsevier

    Dr Joan Genesca

  96. Response to Heish et al.

    Article • The American Journal of Gastroenterology, February 2008, Wolters Kluwer Health

    Dr Joan Genesca

  97. Glucose Abnormalities Are an Independent Risk Factor for Nonresponse to Antiviral Treatment in Chronic Hepatitis C

    Article • The American Journal of Gastroenterology, October 2007, Wolters Kluwer Health

    Dr Joan Genesca

  98. Familial amyloidosis in a large Spanish kindred resulting from a D38V mutation in the transthyretin gene

    Article • European Journal of Clinical Investigation, August 2007, Wiley

    Dr Joan Genesca

  99. Angiomiolipoma hepático en dos pacientes con infección por el virus de la hepatitis C

    Article • Gastroenterología y Hepatología, April 2007, Elsevier

    Dr Joan Genesca

  100. [190] INHIBITION OF ADRENERGIC TRANSMISSION MAY CONTRIBUTE TO SPLANCHNIC VASODILATION IN PORTAL HYPERTENSION

    Article • Journal of Hepatology, April 2007, Elsevier

    Dr Joan Genesca

  101. Sustained Virological Response Correlates With Reduction in the Incidence of Glucose Abnormalities in Patients With Chronic Hepatitis C Virus Infection

    Article • Diabetes Care, October 2006, American Diabetes Association

    Dr Joan Genesca

  102. Proinflammatory Cytokines, Insulin Resistance, and Insulin Secretion in Chronic Hepatitis C patients: A case-control study

    Article • Diabetes Care, May 2006, American Diabetes Association

    Dr Joan Genesca

  103. Glucose Abnormalities in Patients with Hepatitis C Virus Infection: Epidemiology and pathogenesis

    Article • Diabetes Care, May 2006, American Diabetes Association

    Dr Joan Genesca

  104. Glucose Abnormalities in Patients with Hepatitis C Virus Infection: Epidemiology and pathogenesis

    Article • Diabetes Care, April 2006, American Diabetes Association

    Dr Joan Genesca

  105. Proinflammatory Cytokines, Insulin Resistance, and Insulin Secretion in Chronic Hepatitis C patients: A case-control study

    Article • Diabetes Care, April 2006, American Diabetes Association

    Dr Joan Genesca

  106. Hemodynamic response–guided therapy for prevention of variceal rebleeding: An uncontrolled pilot study

    Article • Hepatology, January 2006, Wiley

    Dr Joan Genesca

  107. Diabetes Is the Main Factor Accounting for the High Ferritin Levels Detected in Chronic Hepatitis C Virus Infection: Response to Sebastiani et al.

    Article • Diabetes Care, June 2005, American Diabetes Association

    Dr Joan Genesca

  108. Cardiac alterations in cirrhosis: reversibility after liver transplantation

    Article • Journal of Hepatology, January 2005, Elsevier

    Dr Joan Genesca

  109. Diabetes Is the Main Factor Accounting for the High Ferritin Levels Detected in Chronic Hepatitis C Virus Infection

    Article • Diabetes Care, October 2004, American Diabetes Association

    Dr Joan Genesca

  110. Validation of Automated Blood Cell Counters for the Diagnosis of Spontaneous Bacterial Peritonitis

    Article • The American Journal of Gastroenterology, July 2004, Wolters Kluwer Health

    Dr Joan Genesca

  111. High Prevalence of Glucose Abnormalities in Patients With Hepatitis C Virus Infection: A multivariate analysis considering the liver injury

    Article • Diabetes Care, April 2004, American Diabetes Association

    Dr Joan Genesca

  112. Citocinas y cirrosis hepática

    Article • Medicina Clínica, April 2004, Elsevier

    Dr Joan Genesca

  113. Citocinas y cirrosis hepática

    Article • Medicina Clínica, January 2004, Elsevier

    Dr Joan Genesca

  114. 213 Cirrhotic cardiomyopathy is reversible after liver transplantation

    Article • Journal of Hepatology, January 2004, Elsevier

    Dr Joan Genesca

  115. Increased tumour necrosis factor   production in mesenteric lymph nodes of cirrhotic patients with ascites

    Article • Gut, July 2003, BMJ

    Dr Joan Genesca

  116. Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed

    Article • European Journal of Gastroenterology & Hepatology, July 2003, Wolters Kluwer Health

    Dr Joan Genesca

  117. Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: A double-blind RCT

    Article • Hepatology, June 2003, Wiley

    Dr Joan Genesca

  118. Role of immunosuppression in the development of quinolone-resistant Escherichia coli spontaneous bacterial peritonitis and in the mortality of E. coli spontaneous bacterial peritonitis

    Article • Alimentary Pharmacology & Therapeutics, February 2003, Wiley

    Dr Joan Genesca

  119. Spontaneous bacterial peritonitis caused by quinolone-resistant Escherichia coli: could steroid therapy play a role?

    Article • European Journal of Gastroenterology & Hepatology, January 2002, Wolters Kluwer Health

    Dr Joan Genesca

  120. Isosorbide Mononitrate in the Prevention of First Variceal Bleed in Patients Who Cannot Receive β-blockers

    Article • Gastroenterology, October 2001, Elsevier

    Dr Joan Genesca

  121. Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive β-blockers

    Article • Gastroenterology, October 2001, Elsevier

    Dr Joan Genesca

  122. ROLE OF DOPPLER ECHOCARDIOGRAPHY IN THE ASSESSMENT OF PORTOPULMONARY HYPERTENSION IN LIVER TRANSPLANTATION CANDIDATES1

    Article • Transplantation, February 2001, Wolters Kluwer Health

    Dr Joan Genesca

  123. Islet cell and thyroid antibody prevalence in patients with hepatitis C virus infection: Effect of treatment with interferon

    Article • Journal of Laboratory and Clinical Medicine, January 2001, Elsevier

    Dr Joan Genesca

  124. Nitric oxide may contribute to nocturnal hemodynamic changes in cirrhotic patients

    Article • The American Journal of Gastroenterology, June 2000, Wolters Kluwer Health

    Dr Joan Genesca

  125. Nitric oxide may contribute to nocturnal hemodynamic changes in cirrhotic patients

    Article • The American Journal of Gastroenterology, June 2000, Wolters Kluwer Health

    Dr Joan Genesca

  126. Relación entre los depósitos de hierro y la diabetes mellitus en pacientes infectados por el virus de la hepatitis C: estudio de casos y controles

    Article • Medicina Clínica, January 2000, Elsevier

    Dr Joan Genesca

  127. Soluble Interleukin-6 Receptor Levels in Liver Cirrhosis

    Article • The American Journal of Gastroenterology, October 1999, Wolters Kluwer Health

    Dr Joan Genesca

  128. Correspondence

    Article • The American Journal of Gastroenterology, October 1999, Wolters Kluwer Health

    Dr Joan Genesca

  129. Article • Digestive Diseases and Sciences, January 1999, Springer Science + Business Media

    Dr Joan Genesca

  130. Interleukin-6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis

    Article • The American Journal of Gastroenterology, January 1999, Wolters Kluwer Health

    Dr Joan Genesca

  131. Interleukin-6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis

    Article • The American Journal of Gastroenterology, January 1999, Nature

    Dr Joan Genesca

  132. Correspondence

    Article • The American Journal of Gastroenterology, April 1998, Wolters Kluwer Health

    Dr Joan Genesca

  133. High Levels of Endotoxin Antibodies Contribute to Hyperglobulinemia of Cirrhotic Patients

    Article • The American Journal of Gastroenterology, April 1998, Wolters Kluwer Health

    Dr Joan Genesca

  134. High Prevalence of Hepatitis C Virus Infection in Diabetic Patients

    Article • Diabetes Care, September 1996, American Diabetes Association

    Dr Joan Genesca

  135. Efficacy of screening donors for antibodies to the hepatitis C virus to prevent transfusion-associated hepatitis: Final report of a prospective trial

    Article • Hepatology, August 1995, Wiley

    Dr Joan Genesca

  136. Hepatitis C virus infection in renal transplant recipients: epidemiology, clinical impact, serological confirmation and viral replication

    Article • Journal of Hepatology, March 1995, Elsevier

    Dr Joan Genesca

  137. Hepatitis C virus markers in patients with acute post-transfusion hepatitis treated with interferon alfa-2b.

    Article • Gut, January 1993, BMJ

    Dr Joan Genesca

  138. Reply

    Article • Gastroenterology, November 1992, Elsevier

    Dr Joan Genesca

  139. Interferon-α in acute posttransfusion hepatitis C:. A randomized, controlled trial

    Article • Hepatology, May 1992, Wiley

    Dr Joan Genesca

  140. Evaluation of anti-HCV positive blood donors identified during routine screening

    Article • January 1992, Springer Science + Business Media

    Dr Joan Genesca

  141. High Rate of Infectivity and Liver Disease in Blood Donors with Antibodies to Hepatitis C Virus

    Article • Annals of Internal Medicine, September 1991, American College of Physicians

    Dr Joan Genesca

  142. Blood-Borne Non-A, Non-B Hepatitis: Hepatitis C

    Article • Seminars in Liver Disease, May 1991, Thieme Publishing Group

    Dr Joan Genesca

  143. Genetic variability of the hepatitis C virus. Sequence analysis of the NS3 and 5'UTR

    Article • Journal of Hepatology, January 1991, Elsevier

    Dr Joan Genesca

  144. Second generation HCV EIA evaluation of acute PT-NANBH

    Article • Journal of Hepatology, January 1991, Elsevier

    Dr Joan Genesca

  145. Serum HCV-RNA in anti-HCV-reactive donors according to RIBA-2, liver histology and infectivity

    Article • Journal of Hepatology, January 1991, Elsevier

    Dr Joan Genesca

  146. Detection of hepatitis B virus DNA in serum by PCR after antiviral therapy in patients with chronic hepatitis B

    Article • Journal of Hepatology, January 1991, Elsevier

    Dr Joan Genesca

  147. Clinical Correlation and Genetic Polymorphism of the Human Immunodeficiency Virus Proviral DNA Obtained after Polymerase Chain Reaction Amplification

    Article • The Journal of Infectious Diseases, November 1990, Oxford University Press (OUP)

    Dr Joan Genesca

  148. A randomized controlled trial of α-interferon in acute postransfusion C hepatitis

    Article • Journal of Hepatology, January 1990, Elsevier

    Dr Joan Genesca

  149. WHAT DO WESTERN BLOT INDETERMINATE PATTERNS FOR HUMAN IMMUNODEFICIENCY VIRUS MEAN IN EIA-NEGATIVE BLOOD DONORS?

    Article • The Lancet, October 1989, Elsevier

    Dr Joan Genesca

  150. Hepatitis D virus RNA in acute delta infection: Serological profile and correlation with other markers of hepatitis D virus infection

    Article • Hepatology, September 1988, Wiley

    Dr Joan Genesca

  151. Lack of HIV transmission after hepatitis B immunoprophylaxis

    Article • Infection, September 1987, Springer Science + Business Media

    Dr Joan Genesca

  152. Hepatitis b virus replication in acute hepatitis B, acute hepatitis B virus-hepatitis delta virus coinfection and acute hepatitis delta superinfection

    Article • Hepatology, May 1987, Wiley

    Dr Joan Genesca

  153. Clinical and serological outcome of acute delta infection

    Article • Journal of Hepatology, January 1987, Elsevier

    Dr Joan Genesca

  154. WHEN SHOULD AT-RISK INFANTS BE BOOSTED WITH HEPATITIS B VACCINE?

    Article • The Lancet, January 1987, Elsevier

    Dr Joan Genesca

  155. Immunoprophylaxis of perinatal transmission of the hepatitis B virus: Efficacy of hepatitis B immune globulin and hepatitis B vaccine in a low-prevalence area

    Article • Journal of Medical Virology, April 1986, Wiley

    Dr Joan Genesca